Patentes Internacionales, cuando la ciencia muerde la mano que le da de comer. Por: Julio César Cázares Una situación mundialmente preocupante es la de las patentes, en específico me refiero al intento de Norteamérica de legislar la creación científica mundial y la consecuente explotación por parte de sus empresas hacia todo el mundo. (Con la salvedad que en México como siempre
Denka.co.jpDENKA to strengthen Capital Alliance with SEI Corporation
in the Field of Lithium-ion Secondary Battery Technology
DENKA (president: Shinsuke Yoshitaka) and SEI Corporation (headquarters: Tsu, Mie; representative director: Takehiko Sawai; hereafter “SEI”) have reached an agreement to accelerate the development of electrode material technologies, with a focus on high conductivity (low resistance) materials indispensable to improving the performance of lithium-ion secondary batteries (LiBs). To this end, DENKA has increased its SEI stockholdings from 4.5% to 15%, giving it the second largest stake (after Mr. Takehiko Sawai, who holds 39%) and further strengthening the two companies’ alliance. SEI possesses high conductivity electrode material design technology and is engaged in joint development with Canada-based Hydro-Québec, which holds basic patents related to lithium iron phosphate (LFP). Through its capital alliance with SEI, DENKA has previously created specialty composites combining LFP with carbon nanofiber and DENKA BLACK (acetylene black), realizing tremendous increases in LFP conductivity and improvements in the discharge rate and charge-discharge cycle. Looking ahead, demand for automobile-use LiBs is expected to show a particular increase, and high-capacity, high-output materials, such as nickel-manganese-cobalt ternary materials and manganese spinel materials, are expected to become the mainstream cathode materials used in such batteries. New, highly conductive materials for use in anodes are also being investigated. Increasing conductivity wil be one of the most important chal enges to address in implementing these technologies going forward. With the construction of a new, dedicated production facility at DENKA’s Chiba Plant (Ichihara, Chiba) for ultrahigh purity acetylene black for use in LiBs, DENKA is working to significantly improve product quality and build a robust supply system. At the same time, through our capital alliance with SEI, we are speeding up the development of technology to increase the conductivity of various electrode materials. Furthermore, we aim to provide comprehensive solutions related to LiB parts and materials. As we approach the centennial anniversary of our founding in 2015, we are promoting the DENKA
100 management plan (for details, please see the April 10, 2013 news release on our corporate
website). One of the growth strategies of this plan is to focus management resources on new
growth drivers and develop next-generation products. The development of LiB materials relates to
such growth drivers as the environment and energy.
We have included an outline of SEI Corporation below, for reference.
For more information about DENKA BLACK, please visit our website:
Corporate Planning Department
Outline of SEI Corporation
November 11, 1999 (November 11 is designated as Battery Day by the Battery Association of Japan) A venture enterprise operating in three business fields under the motto
“Achieve: Setting business goals and helping make technologies and products a
reality by leveraging all five senses.”
Continuous development of long-life, low-resistance, low-cost battery materials; solving technical chal enges in producing slurry for lithium-ion batteries; supplying prototype lithium-ion battery cells External battery packs for smartphones, contactless chargers for tablet computers Engaged in the joint development of LEDs, memory, semiconductor chips, diodes, and, particularly, LiBs with leading overseas companies, including Canada-based Hydro-Québec, which holds patents related to LFP
Depo Provera Depo what ???? What is it? Depo Provera is an injectable contraceptive. Also known as DMPA, it is extremely effective partly because it is forgiving if a woman returns several days to 2 weeks late for an injection. DMPA has been used by more than 20 million women worldwide, and is approved for use in more than 90 countries, including the US, where it was approved in 1992.